Noxiptiline

From Wikipedia, the free encyclopedia
Noxiptiline
Skeletal formula of noxiptilin
Space-filling model of the noxiptiline molecule
Clinical data
Trade namesAgedal, Elronon, Nogedal
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-one O-[2-dimethylamino)ethyl]oxime
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H22N2O
Molar mass294.398 g·mol−1
3D model (JSmol)
SMILES
  • O(\N=C2\c1c(cccc1)CCc3c2cccc3)CCN(C)C
InChI
  • InChI=1S/C19H22N2O/c1-21(2)13-14-22-20-19-17-9-5-3-7-15(17)11-12-16-8-4-6-10-18(16)19/h3-10H,11-14H2,1-2H3 checkY
  • Key:GPTURHKXTUDRPC-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  

Noxiptiline (brand names Agedal, Elronon, Nogedal), also known as noxiptyline and dibenzoxine, is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1970s for the treatment of depression.[1][2][3] It has imipramine-like effects,[4] acting as a serotonin and norepinephrine reuptake inhibitor, among other properties.[5][6] Of the TCAs, noxiptiline has been described as one of the most effective, rivaling amitriptyline in clinical efficacy.[7][8]

References[]

  1. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 753. ISBN 3-88763-075-0.
  2. ^ Aronson, Jeffrey Kenneth (2008). Meyler's Side Effects of Psychiatric Drugs (Meylers Side Effects). Amsterdam: Elsevier Science. p. 34. ISBN 978-0-444-53266-4.
  3. ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. p. 4868. ISBN 0-412-54090-8.
  4. ^ Mutschler, Ernst (1995). Drug actions: basic principles and therapeutic aspects. Stuttgart, Germany: Medpharm Scientific Pub. p. 127. ISBN 0-8493-7774-9. Retrieved January 30, 2013.
  5. ^ Ernst Jucker; S. Ren; Soudijn, W.; Wijngaarden, I. van; M. Kumari; D. Poyner; M. Bushfield; H. Horikoshi; Fujiwara, Tamenari (2000). Progress in Drug Research, Volume 54 (Progress in Drug Research). Boston: Birkhauser. p. 81. ISBN 3-7643-6113-1.
  6. ^ Barth N, Manns M, Muscholl E (1975). "Arrhythmias and inhibition of noradrenaline uptake caused by tricyclic antidepressants and chlorpromazine on the isolated perfused rabbit heart". Naunyn-Schmiedeberg's Archives of Pharmacology. 288 (2–3): 215–31. doi:10.1007/BF00500528. PMID 1161046. S2CID 11641400.
  7. ^ Beresewicz M, Bidzińska E, Koszewska I, Puzyński S (1991). "[Results of using tricyclic antidepressive drugs in the treatment of endogenous depression (comparative analysis of 7 drugs)]". Psychiatria Polska (in Polish). 25 (3–4): 13–8. PMID 1687987.
  8. ^ Lingjaerde O, Asker T, Bugge A, et al. (January 1975). "Noxiptilin (Agedal)--a new tricyclic antidepressant with a faster onset of action? A double-blind, multicentre comparison with amitriptyline". Pharmakopsychiatrie, Neuro-Psychopharmakologie. 8 (1): 26–35. doi:10.1055/s-0028-1094440. PMID 788000.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""